CellaVision (CEVI) Stock Overview
Develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
CEVI passed our risk checks.
CEVI Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CellaVision AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 162.20 |
| 52 Week High | SEK 192.20 |
| 52 Week Low | SEK 117.60 |
| Beta | 0.97 |
| 1 Month Change | 12.02% |
| 3 Month Change | 32.95% |
| 1 Year Change | -6.57% |
| 3 Year Change | -9.99% |
| 5 Year Change | -64.75% |
| Change since IPO | 939.74% |
Recent News & Updates
Narrative Update • Jul 21
CEVI: Fair Value View Will Balance CEO Transition And Recent Downgrade
Analysts have raised their fair value estimate for CellaVision to SEK 160 from SEK 140, citing updated assumptions for revenue growth, profit margins, and a slightly lower discount rate, even as the latest Street research reflects a Hold stance with a SEK 150 price target. What's in the News for CellaVision CellaVision appointed Steve Ferguson as the new Chief Executive Officer, with the role effective June 5, 2026.Analysis Article • Jul 21
CellaVision AB (publ) Just Beat Revenue By 7.7%: Here's What Analysts Think Will Happen Next
CellaVision AB (publ) ( STO:CEVI ) defied analyst predictions to release its quarterly results, which were ahead of...
Narrative Update • Jul 07
CEVI: New Leadership And Higher Margins Will Support Future Upside
Analysts have lowered their CellaVision price target from SEK211 to SEK180, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for CellaVision CellaVision appointed Steve Ferguson as Chief Executive Officer, effective June 5, 2026.
Narrative Update • Jun 22
CEVI: New Leadership And Stable Margins Will Support Future Upside
Analysts have kept their price target for CellaVision steady at SEK 179, reflecting largely unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. What’s in the News for CellaVision CellaVision appointed Steve Ferguson as the new Chief Executive Officer, with the change taking effect on June 05, 2026.Recent updates
Narrative Update • Jul 21
CEVI: Fair Value View Will Balance CEO Transition And Recent Downgrade
Analysts have raised their fair value estimate for CellaVision to SEK 160 from SEK 140, citing updated assumptions for revenue growth, profit margins, and a slightly lower discount rate, even as the latest Street research reflects a Hold stance with a SEK 150 price target. What's in the News for CellaVision CellaVision appointed Steve Ferguson as the new Chief Executive Officer, with the role effective June 5, 2026.Analysis Article • Jul 21
CellaVision AB (publ) Just Beat Revenue By 7.7%: Here's What Analysts Think Will Happen Next
CellaVision AB (publ) ( STO:CEVI ) defied analyst predictions to release its quarterly results, which were ahead of...Narrative Update • Jul 07
CEVI: New Leadership And Higher Margins Will Support Future Upside
Analysts have lowered their CellaVision price target from SEK211 to SEK180, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for CellaVision CellaVision appointed Steve Ferguson as Chief Executive Officer, effective June 5, 2026.Narrative Update • Jun 22
CEVI: New Leadership And Stable Margins Will Support Future Upside
Analysts have kept their price target for CellaVision steady at SEK 179, reflecting largely unchanged assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. What’s in the News for CellaVision CellaVision appointed Steve Ferguson as the new Chief Executive Officer, with the change taking effect on June 05, 2026.Narrative Update • Jun 07
CEVI: Bone Marrow Rollout And Stable Margins Will Support Future Upside
Analysts have kept their SEK 179.0 price target for CellaVision broadly unchanged, citing only small tweaks to assumptions around discount rate, long term revenue growth, profit margin and future P/E that leave their overall valuation view effectively steady. What's in the News CellaVision launched its CellaVision Bone Marrow Aspirate (BMA) Application across the EMEA region, extending its digital cell morphology platform into bone marrow aspirate analysis.Narrative Update • May 24
CEVI: Bone Marrow Expansion And Steady Margins Will Support Future Upside
Analysts now keep their SEK price target for CellaVision effectively unchanged at around SEK 179. This reflects only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than a shift in their overall view of the stock.New Narrative • May 14
Digital Cell Analysis And New Applications Will Drive Long Term Upside Potential
Catalysts About CellaVision CellaVision develops digital microscopy solutions that help clinical laboratories automate and standardize blood and bone marrow cell analysis. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 30
CEVI: Bone Marrow Launch And Dividend Will Support Future Upside
Analysts have trimmed their CellaVision price target from SEK225 to SEK179. This reflects updated assumptions for slightly lower revenue growth, profit margins and future P/E, alongside a higher discount rate in their models.New Narrative • Apr 29
Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications
Catalysts About CellaVision CellaVision develops digital microscopy and software solutions for hematology laboratories worldwide. What are the underlying business or industry changes driving this perspective?Analysis Article • Nov 09
CellaVision AB (publ) (STO:CEVI) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Shareholders might have noticed that CellaVision AB (publ) ( STO:CEVI ) filed its third-quarter result this time last...Analysis Article • Aug 22
Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
While CellaVision AB (publ) ( STO:CEVI ) might not have the largest market cap around , it saw a decent share price...Analysis Article • Jul 23
Here's What Analysts Are Forecasting For CellaVision AB (publ) (STO:CEVI) After Its Second-Quarter Results
Shareholders might have noticed that CellaVision AB (publ) ( STO:CEVI ) filed its second-quarter result this time last...Analysis Article • May 04
There's Reason For Concern Over CellaVision AB (publ)'s (STO:CEVI) Massive 29% Price Jump
Those holding CellaVision AB (publ) ( STO:CEVI ) shares would be relieved that the share price has rebounded 29% in the...Analysis Article • Apr 30
Is There Now An Opportunity In CellaVision AB (publ) (STO:CEVI)?
CellaVision AB (publ) ( STO:CEVI ), is not the largest company out there, but it led the OM gainers with a relatively...Analysis Article • Apr 03
CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.50
CellaVision AB (publ) ( STO:CEVI ) has announced that it will be increasing its dividend from last year's comparable...
New Narrative • Feb 13
Next-generation Digital Cell Morphology Analyzer Will Drive Future Product Development
Strategic alignment with Sysmex and innovation are driving growth, enhancing revenue and future earnings potential.Analysis Article • Feb 11
CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.50
CellaVision AB (publ) ( STO:CEVI ) will increase its dividend on the 13th of May to SEK2.50, which is 11% higher than...Analysis Article • Feb 10
Analyst Estimates: Here's What Brokers Think Of CellaVision AB (publ) (STO:CEVI) After Its Annual Report
CellaVision AB (publ) ( STO:CEVI ) just released its latest annual report and things are not looking great. Results...Analysis Article • Feb 08
CellaVision AB (publ)'s (STO:CEVI) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 31.9x CellaVision AB (publ) ( STO:CEVI ) may be sending bearish signals at...Analysis Article • Jan 21
Is Now The Time To Put CellaVision (STO:CEVI) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Nov 20
Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Oct 27
CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, CellaVision AB (publ) ( STO:CEVI ) last week released its latest quarterly, and things did not turn...Analysis Article • Jul 24
CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's shaping up to be a tough period for CellaVision AB (publ) ( STO:CEVI ), which a week ago released some...Analysis Article • Jun 07
Is CellaVision (STO:CEVI) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 22
Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Apr 13
CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25
The board of CellaVision AB (publ) ( STO:CEVI ) has announced that it will pay a dividend of SEK2.25 per share on the...Analysis Article • Apr 09
CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, CellaVision fair value estimate is kr313 CellaVision is...Analysis Article • Mar 28
CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
CellaVision AB (publ) ( STO:CEVI ) has announced that it will pay a dividend of SEK2.25 per share on the 13th of May...Analysis Article • Mar 14
CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
CellaVision AB (publ)'s ( STO:CEVI ) investors are due to receive a payment of SEK2.25 per share on 13th of May. This...Analysis Article • Feb 29
CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
The board of CellaVision AB (publ) ( STO:CEVI ) has announced that it will pay a dividend of SEK2.25 per share on the...Analysis Article • Feb 16
After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Despite an already strong run, CellaVision AB (publ) ( STO:CEVI ) shares have been powering on, with a gain of 28% in...Analysis Article • Feb 12
CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
The board of CellaVision AB (publ) ( STO:CEVI ) has announced that it will pay a dividend of SEK2.25 per share on the...Analysis Article • Feb 10
Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
CellaVision AB (publ) ( STO:CEVI ) investors will be delighted, with the company turning in some strong numbers with...Analysis Article • Dec 13
CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Shareholder Returns
| CEVI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 6.4% | 1.6% | -1.1% |
| 1Y | -6.6% | -0.7% | 10.6% |
Return vs Industry: CEVI underperformed the Swedish Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: CEVI underperformed the Swedish Market which returned 10.6% over the past year.
Price Volatility
| CEVI volatility | |
|---|---|
| CEVI Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.1% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: CEVI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CEVI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 251 | Steve Ferguson | www.cellavision.com |
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials.
CellaVision AB (publ) Fundamentals Summary
| CEVI fundamental statistics | |
|---|---|
| Market cap | SEK 3.74b |
| Earnings (TTM) | SEK 129.09m |
| Revenue (TTM) | SEK 739.15m |
30.0x
P/E Ratio5.2x
P/S RatioIs CEVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEVI income statement (TTM) | |
|---|---|
| Revenue | SEK 739.15m |
| Cost of Revenue | SEK 231.28m |
| Gross Profit | SEK 507.87m |
| Other Expenses | SEK 378.78m |
| Earnings | SEK 129.09m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 29, 2026
| Earnings per share (EPS) | 5.41 |
| Gross Margin | 68.71% |
| Net Profit Margin | 17.46% |
| Debt/Equity Ratio | 5.9% |
How did CEVI perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield51%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 17:39 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellaVision AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |